Advances in ROS1-positive NSCLC treatment landscape
23 Sep 2025
byDr. Herbert Loong, Department of Clinical Oncology, t the Chinese University of Hong Kong; Dr. James Ho, School of Clinical Medicine, University of Hong Kong; Dr. Molly Li, Department of Clinical Oncology, Chinese University of Hong Kong; Prof. Byoung-Chul Cho, Yonsei Cancer Center at Severance Hospital, Seoul, South Korea; Prof. Beung-Chul Ahn, National Cancer Centre, Seoul, Korea
ROS1 rearrangement is an actionable mutation present in 2–3 percent of Chinese patients with advanced non-small-cell lung cancer (NSCLC). At an industry-sponsored meeting chaired by Dr Herbert Loong of the Department of Clinical Oncology at the Chinese University of Hong Kong (CUHK), experts discussed challenges in ROS1-positive NSCLC management, presented clinical data and shared real-world experience of using repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), in TKI-naïve and -experienced patients.
